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ABSTRACT
Background & aims: Although the Rome III criteria for functional dyspepsia were
defined 7 years ago, they have yet to be validated in a rigorous study. We addressed
this issue in a secondary-care population.
Methods:We analyzed complete symptom, upper gastrointestinal (GI) endoscopy,
and histology data from 1452 consecutive adult patients with GI symptoms at 2
hospitals in Hamilton, Ontario. Assessors were blinded to symptom status. Individuals
with normal upper GI endoscopy and histopathology findings from analyses of biopsy
specimens were classified as having no organic GI disease. The reference standard
used to define presence of true FD was epigastric pain, early satiety or post-prandial
fullness, and no organic GI disease. Sensitivity, specificity, and positive and negative
likelihood ratios (LRs), with 95% confidence intervals (CIs), were calculated.
Results: Of the 1452 patients, 722 (49.7%) met Rome III criteria for FD. Endoscopy
revealed organic GI disease in 170 patients (23.5%) who met the Rome III criteria.
The Rome III criteria identified patients with functional dyspepsia with 60.7%
sensitivity, 68.7% specificity, a positive LR of 1.94 (95% CI, 1.69–2.22), and a
negative LR of 0.57 (95% CI, 0.52–0.63). In contrast, the Rome II criteria identified
patients with functional dyspepsia with 71.4% sensitivity, 55.6% specificity, a
positive LR of 1.61 (95% CI, 1.45–1.78), and a negative LR of 0.51 (95% CI, 0.45–
0.58). The area under a receiver operating characteristics curves did not differ
significantly for any of the diagnostic criteria for functional dyspepsia.
Conclusions: In a validation study of 1452 patients with GI symptoms, the Rome III
criteria performed only modestly in identifying those with functional dyspepsia, and
were not significantly superior to previous definitions.
Keywords: Functional dyspepsia; Rome III criteria; accuracy; sensitivity; specificity
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INTRODUCTION
Dyspepsia is a symptom complex referable to the upper gastrointestinal (GI)
tract. The prevalence of dyspepsia in the community varies between 5% and 40%,
depending on the geographical region under study, but also on the criteria used to
define its presence. 1-4 The condition has significant implications both for sufferers,
due to impaired quality of life and sickness absence from work, 5-9 and society as a
whole, due to medical expenses arising from managing the condition. A recent
questionnaire survey reported that the mean yearly cost of dyspepsia to patients was
almost $700, 10 and burden of illness studies in the USA estimated that there were
almost 2 million physician visits in 2009 as a result of dyspepsia, 11 and >30% of
endoscopies were performed with dyspepsia as the main indication. 12 Despite this,
dyspepsia does not appear to impact adversely on survival. 13, 14
The cost of managing dyspepsia may be reduced if upper GI symptoms could
accurately distinguish between organic and functional dyspepsia (FD), but a
systematic review has suggested that symptoms perform poorly in this regard. 15 The
commonest organic finding at upper GI endoscopy in Western populations with
dyspepsia is erosive esophagitis, 16 and over the last 20 years definitions of the
condition have been refined substantially, 17-20 with the main aim of excluding
patients with gastro-esophageal reflux disease (GERD), in an attempt to enrich the
number of patients with FD.
The latest definition of FD is the Rome III criteria, 18 which consist of one or
more of the following symptoms: epigastric pain or burning, postprandial fullness
after a normal sized meal, or early satiety. This is stricter than previous definitions of
FD in excluding patients with reflux symptoms, and should therefore classify fewer
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patients with GERD incorrectly as having FD. The Rome III criteria were published
over 7 years ago and yet there has been little in the way of validation of these criteria.
We have therefore evaluated their accuracy in identifying patients with FD in a
secondary care setting. We also compared Rome III with previous definitions of FD to
assess whether they are superior to other approaches, and in particular whether they
perform better in excluding patients with erosive esophagitis.
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METHODS
Participants and Setting
This study was conducted among patients newly referred from primary care to
secondary care for consideration of investigation of upper or lower GI symptoms.
8QVHOHFWHGFRQVHFXWLYHQHZSDWLHQWVDJHG\HDUVZHUHDSSURDFKHGLQWKH*,
outpatient clinics of McMaster University Medical Center or St. Joseph’s Healthcare,
two hospitals in Hamilton, Ontario serving a local population of 520,000. During a
monitoring period from January 2012 to December 2012, 26% of the referrals to the
clinics were tertiary care in nature. There were no exclusion criteria, other than an
inability to understand written English. Potentially eligible subjects were provided
with a patient information leaflet about the study at their initial clinic visit, prior to
consultation with a Gastroenterologist. Those who agreed to participate were asked to
provide written informed consent at that visit. The Hamilton Health Sciences and
McMaster University research ethics board approved the study in January 2008, and
recruitment ended in December 2012. We have previously conducted a validation
study of the Rome III criteria for irritable bowel syndrome among individuals with
lower GI symptoms undergoing colonoscopy using this dataset. 21 In this study we set
out to validate the Rome III criteria for FD among individuals with upper GI
symptoms undergoing upper GI endoscopy.
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Data Collection and Synthesis
Demographic and Symptom Data
All demographic and symptom data were collected prospectively at the initial
clinic visit, and hence prior to referral for upper GI endoscopy. Basic demographic
data included age, gender, ethnicity, marital status, educational level, lifestyle
(tobacco and alcohol use), height (in meters), and weight (in kilograms), which were
used to calculate body mass index (BMI). Symptom data were captured using the
Rome III diagnostic questionnaire for the adult functional GI disorders, 22 but we also
collected data in order to examine the accuracy of the Rome II criteria, 20 and a broad
definition in line with the 1988 working party report, 17 in diagnosing FD. All
questionnaire data were entered into a database by a trained researcher, who was not
involved with the clinical care of the patients, thus ensuring assessors were blinded to
symptom status.
Definitions of FD
The presence or absence of Rome III-defined FD among individual patients
was assigned according to the scoring algorithm proposed for use with the Rome III
questionnaire, which is detailed in Supplementary Table 1. As the questionnaire
contained other symptom items, we were also able to classify the presence or absence
of FD according to the following previously accepted gold-standard symptom-based
criteria, which preceded the Rome III criteria: the Rome II criteria, 20 and a broad
definition of FD (see supplementary Table 1). 17
The questionnaire also contained the individual symptom items used to
subtype Rome III FD, allowing us to classify the presence or absence of epigastric
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pain syndrome (EPS) and postprandial distress syndrome (PDS) (Supplementary
Table 1). As the definition of EPS is very restrictive, we performed a sensitivity
analysis where EPS was defined using only the presence of symptoms >once per
ZHHNIRUPRQWKVZLWKRXWDSSO\LQJWKHRWKHUUHTXLUHGIHDWXUHV,QDGGLWLRQDVWKH
definition of PDS does not exclude heartburn we performed a sensitivity analysis
where those reporting this symptom at a frequency of >once per month were excluded
from the definition.
Endoscopic and Histopathological Data
All included patients underwent complete upper GI endoscopy to the second
part of the duodenum, using Pentax endoscopes (Pentax Canada, Inc), following a 6-
hour fast. The responsible physician performing upper GI endoscopic examinations
remained blinded to the questionnaire data of the patient. Findings were recorded
using the endoPRO reporting system (Pentax Canada, Inc), and study investigators
accessed these reports to record the ultimate endoscopic diagnosis for each included
patient. We classified the following findings as being consistent with organic disease
at upper GI endoscopy: evidence of erosive esophagitis, Barrett’s esophagus, benign
esophageal stricture, Schatzki ring, esophageal carcinoma, esophageal candidiasis,
gastric ulcer, gastric cancer, or duodenal ulcer. Cystic fundic gland polyps, gastritis
diagnosed after histological interpretation of gastric biopsy specimens, or duodenitis,
defined as erythema in the duodenum seen at upper GI endoscopy, were not
considered to represent organic disease. However, gastric or duodenal erosions were
classified as organic in nature, and were reported separately from peptic ulcer, unless
WKHUHZHUHJDVWULFHURVLRQVLQZKLFKFDVHWKHSDWLHQWZDVFODVVLILHGDVKDYLQJ
gastric ulcer.
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Biopsy specimens were obtained at the discretion of the responsible physician
performing the upper GI endoscopy. Experienced GI histopathologists, who remained
blinded to the questionnaire data of the patient, interpreted these biopsies.
Histopathological findings were recorded using the MEDITECH Healthcare
Reporting System (Medical Information Technology Inc, Westwood, MA, USA), and
this was accessed by the study investigators in order to record the ultimate
histopathological diagnosis. We classified the following findings as being consistent
with organic disease at histopathological examination of biopsy specimens: Barrett’s
esophagus, reflux or eosinophilic esophagitis, esophageal squamous cell or
adenocarcinoma, esophageal candidiasis, gastric adenocarcinoma, gastric carcinoid,
upper GI Crohn’s disease, celiac disease, villous atrophy due to other causes, or
duodenal adenocarcinoma.
Definition of Organic Upper GI disease
Using these data we were able to classify patients according to the presence or
absence of organic upper GI disease. Individuals with no evidence of organic disease
at both upper GI endoscopy and histopathological examination of biopsy specimens
were classified as exhibiting no organic upper GI disease, while those with evidence
of organic disease at either upper GI endoscopy or histopathological examination of
biopsy specimens were classified as exhibiting organic upper GI disease.
Reference Standard
The reference standard used to define the presence of true FD was the
presence of any of epigastric pain or burning, postprandial fullness, or early satiety in
a patient who exhibited no evidence of organic upper GI disease after upper GI
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endoscopy and histological interpretation of biopsies (if obtained) that would explain
these symptoms. The reference standard used to define presence of EPS was the
presence of any degree of epigastric pain or burning, in a patient who exhibited no
evidence of organic upper GI disease after upper GI endoscopy and normal
histological interpretation of biopsies (if obtained). The reference standard used to
define PDS was the presence of any degree of postprandial fullness or early satiety,
again in a patient who exhibited no evidence of organic upper GI disease after upper
GI endoscopy and histological interpretation of biopsies (if obtained).
Statistical Analysis
In order to assess whether those who underwent upper GI endoscopy were
representative of all patients seen in the two GI outpatient clinics demographic data
were compared between those undergoing upper GI endoscopy who completed the
symptom questionnaire, and those who completed the symptom questionnaire but did
QRWXQGHUJRXSSHU*,HQGRVFRS\XVLQJDȤ2 test for categorical data, and an
independent samples t-test for continuous data, with a mean and standard deviation
(SD). Due to multiple comparisons a 2-tailed P value of <0.01 was considered
statistically significant for these analyses. We compared organic findings in those
meeting the Rome III criteria for FD with those who did not, as well as according to
FD symptom subtype, using Fisher’s exact test, as numbers in each cell were
relatively small. These statistical analyses were performed using SPSS for Windows
version 19.0 (SPSS Inc, Chicago, IL, USA).
The primary aim of the study was to describe the performance of the Rome III
criteria for FD in evaluating the presence of true FD versus the reference standard.
However, we also wanted to compare the performance of the Rome III criteria for FD
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with previously available symptom-based diagnostic criteria including the Rome II
criteria, and a broad definition of FD, as well as the performance of the Rome III FD
symptom subtypes of EPS and PDS. The sensitivity, specificity, and positive and
negative predictive values, and their 95% confidence intervals (CIs), were calculated
for each of these using a Microsoft Excel spreadsheet (XP professional edition;
Microsoft Corp, Redmond, WA, USA). The positive likelihood ratio (LR) and
negative LR, and their 95% CIs, were also calculated using the same spreadsheet. The
positive LR can be calculated from the formula: positive LR = sensitivity / (1-
specificity), while the negative LR is derived from the formula: negative LR = (1-
sensitivity) / specificity. These calculations were checked using Meta-DiSc® version
1.4 (Universidad Complutense, Madrid, Spain). The area under a receiver operating
characteristics curve, with a 95% CI, was calculated for each of these three definitions
of FD using SPSS for Windows version 19.0 (SPSS Inc, Chicago, IL, USA), and this
was compared between the three using a one-way analysis of variance.
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RESULTS
There were a total of 4224 consecutive new patients who gave informed
consent and were recruited into the study between January 2008 and December 2012
(Figure 1). The mean age of recruited subjects was 47.6 years (range 16 to 93 years)
and 2617 (62.0%) were female. In total, 1605 (38.0%) of these 4224 patients
underwent complete endoscopic evaluation for their upper GI symptoms. The mean
age among those undergoing upper GI endoscopy was 48.9 years (range 16 to 91),
and 1018 (63.4%) were female.
Characteristics of Included Individuals
There were 1452 individuals providing complete symptom, upper GI
endoscopy, and histology data. Demographic data of all these patients, compared with
the 2619 subjects who did not undergo upper GI endoscopy, are provided in Table 1.
Those undergoing upper GI endoscopy were slightly older, were less likely to be
White Caucasian, and were more likely to meet the Rome III criteria for FD, but there
were no other significant differences in demographics between the two groups.
In total, 722 (49.7%) of the 1452 patients undergoing upper GI endoscopy met
the Rome III criteria for FD. The mean age of these 722 individuals was 46.4 years,
and 496 (68.7%) were female. Organic pathology was detected at upper GI endoscopy
in 170 (23.5%) of the 722 patients meeting the Rome III criteria for FD, with 29
individuals demonstrating more than one pathology. Erosive esophagitis and peptic
ulcer disease were the commonest, occurring in 11.2% and 7.8% of individuals
respectively, while gastro-esophageal malignancy was extremely rare, occurring in
only two patients (0.28%). The prevalence of individual organic findings after upper
Ford et al. 14 of 39
GI endoscopy and examination of biopsies, where obtained, in those who met the
Rome III criteria for FD, compared with those who did not, are detailed in Table 2.
The only significant difference was the prevalence of eosinophilic esophagitis, which
was commoner among those who did not meet the Rome III criteria for FD (1.6%
versus 0.1%, P = 0.003).
Of the 722 individuals with dyspepsia, 24 (3.3%) met criteria for EPS alone,
663 (91.8%) met criteria for PDS alone, and 35 (4.8%) met criteria for both EPS and
PDS, giving a prevalence for EPS among those undergoing endoscopy of 4.1%,
compared with 48.1% for PDS. Organic findings according to FD symptom subtype
are provided in Table 3. When the less restrictive definition of EPS was used there
were 851 individuals with dyspepsia, 153 (18.0%) of whom met criteria for EPS
alone, 347 (40.8%) met criteria for PDS alone, and 351 (41.2%) met criteria for both
EPS and PDS. This gave a prevalence of EPS among those undergoing endoscopy of
34.7%, compared with 48.1% for PDS.
Validation of the Rome III Criteria for FD
Among the 909 patients with a diagnosis of FD according to the reference
standard following upper GI endoscopy, 552 met the Rome III criteria for FD, giving
a sensitivity of 60.7% (Table 4). Among 543 subjects who were not judged to have
FD according to the reference standard, 373 did not meet the Rome III criteria, giving
a specificity of 68.7%. The positive LR of the Rome III criteria for the diagnosis of
FD was therefore 1.94 (95% CI 1.69 to 2.22), while the negative LR was 0.57 (95%
CI 0.52 to 0.63). The area under the receiver operating characteristics curve for the
Rome III criteria was 0.65 (95% CI 0.62 to 0.68).
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Validation of the Rome III Symptom Subtypes for FD
We also compared the performance of the two dyspepsia symptom
subtypes, EPS and PDS, against their reference standards. We report the results of
these analyses in the supplementary materials provided online.
Degree of Overlap Between FD Symptom Subtypes
Among the 552 individuals who met the Rome III criteria for FD, and who
were confirmed as having FD according to the gold-standard, complete symptom data
were available for EPS and PDS subtypes in 538. Of these, 16 (3.0%) met criteria for
EPS alone, 489 (90.9%) met criteria for PDS alone, and 33 (6.1%) met criteria for
both. When the less restrictive definition of EPS was used, the degree of overlap
increased considerably, with 16 (3.0%) patients having EPS alone, 241 (44.8%)
meeting criteria for PDS alone, and 281 (52.2%) meeting criteria for both.
Validation of the Rome II Criteria for FD
Among the 947 patients with a diagnosis of FD according to the reference
standard, 676 met the Rome II criteria for FD, giving a sensitivity of 71.4% (Table 4).
Among 550 subjects who were not judged to have FD according to the reference
standard, 306 did not meet the Rome II criteria, giving a specificity of 55.6%. The
positive LR of the Rome II criteria for the diagnosis of FD was therefore 1.61 (95%
CI 1.45 to 1.78), while the negative LR was 0.51 (95% CI 0.45 to 0.58). The area
under the receiver operating characteristics curve for the Rome II criteria was 0.64
(95% CI 0.61 to 0.67).
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Validation of a Broad Definition of FD
Among the 988 patients with a diagnosis of FD according to the reference
standard following upper GI endoscopy, 909 met the broad definition for FD, giving a
sensitivity of 92.0% (Table 4). Among 559 subjects who were not judged to have FD
according to the reference standard, 160 did not report symptoms compatible with a
broad definition of FD, giving a specificity of 28.6%. The positive LR of a broad
definition of FD was therefore 1.29 (95% CI 1.22 to 1.36), while the negative LR was
0.28 (95% CI 0.22 to 0.36). The area under the receiver operating characteristics
curve for a broad definition of FD was 0.61 (95% CI 0.58 to 0.64).
Comparison of the Definitions of FD
There was no statistically significant difference between the area under the
receiver operating characteristics curve for Rome III, Rome II or a broad definition of
FD (P = 0.15, repeated measures one-way analysis of variance).
Prevalence of Erosive Esophagitis According to FD Definition
Among the 722 patients with Rome III-defined FD, 81 (11.2%; 95% CI 9.1%
to 13.7%) were found to have erosive esophagitis at upper GI endoscopy. This
compared with 104 (11.2%; 95% CI 9.3% to 13.4%) of 931 subjects meeting the
Rome II criteria for FD, and 157 of (11.8%; 95% CI 10.2% to 13.7%) 1327
individuals who reported symptoms compatible with a broad definition of FD.
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DISCUSSION
This study has attempted to validate the Rome III criteria for FD against an
accepted reference standard. It has demonstrated that these criteria perform only
modestly in predicting a diagnosis of FD in a patient with upper GI symptoms, with
their presence increasing the likelihood of having FD by around two-fold, whilst their
absence reduces the likelihood of FD by approximately 40%. When the individual
symptom subtypes of EPS and PDS were examined, the presence of EPS increased
the likelihood of FD by over six-fold, but the negative LR was poor at 0.94. The less
restrictive definition of EPS performed much better, in terms of the negative LR
which was 0.50, and the positive LR remained above 4. The criteria for PDS
performed similarly in terms of negative LR, but the positive LR was less than 3.
Refining the criteria for PDS led to an improvement in the positive, but not the
negative, LR. Prevalence of the EPS subtype was only 4% in our primary analysis,
due to the restrictive nature of the Rome III definition. When the definition was
relaxed in our sensitivity analysis the prevalence increased to almost 35%. In both
analyses >50% of individuals with EPS also met criteria for PDS, questioning the
clinical relevance of these subtypes.
The Rome III criteria performed similarly to the Rome II criteria, in terms of
the positive and negative LRs obtained. However, the positive LR of the Rome III
criteria was higher than that for a broad definition of FD, although the negative LR for
a broad definition was lower. Analysis of the area under the receiver operating
characteristics curve for all three diagnostic criteria demonstrated very similar results,
with overlapping 95% CIs, and there was no statistically significant difference in their
performance. Despite one of the rationales for the revision of the Rome III criteria
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being to allow separation of FD and GERD more clearly, almost identical proportions
of patients meeting criteria for each of the different definitions of FD we studied were
found to have erosive esophagitis at upper GI endoscopy.
Strengths of this study include the large sample size, with >1400 individuals
undergoing upper GI endoscopy and providing complete symptom data. We also
validated the two FD symptom subtypes of EPS and PDS, and performed a sensitivity
analysis using a less restrictive definition of EPS, and a more restrictive definition of
PDS. In addition, the study was designed to adhere closely to the STARD guidelines
for the reporting of studies of diagnostic accuracy, with consecutive patients recruited,
assessors blinded, and an accepted reference standard used. Finally, the fact that the
majority of patients we recruited were unselected referrals to secondary care means
that the results are likely to be generalizable to Gastroenterologists consulting with
individuals with suspected FD in usual clinical practice, but not to a primary care
setting, where many patients with FD are managed.
Weaknesses of the study include the fact that we did not mandate endoscopy
in all individuals with upper GI symptoms as part of the study design. This means that
patients were managed according to the judgment of the physician they were
consulting with. There were a total of 750 patients who also met the Rome III criteria
for FD but who did not undergo endoscopy, and if the diagnosis were also correct in
this group of patients then the true positive rate of the Rome III criteria will have been
artificially reduced, leading to an underestimation of their accuracy. In addition, those
who did undergo endoscopy and provide complete symptom data were not entirely
representative of the entire study population, with an under representation of White
Caucasians, younger individuals, and alcohol users. However, in most cases the
absolute differences in demographic data between those undergoing endoscopy and
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providing complete symptom data and those who did not were modest. The reference
standard included symptom data from the questionnaire, although if anything this
would have led to an overestimation of the accuracy of the Rome III criteria for FD.
As the presence of any degree of erosive esophagitis at upper GI endoscopy was
classed as an organic disease, regardless of correlation with symptoms, this may have
led to misclassification of patients with true FD as organic disease, hence
underestimating the sensitivity and positive predictive value of the Rome III criteria.
Finally, the decision to take biopsies at upper GI endoscopy was in the hands of the
responsible physician, and there is likely to be considerable variability between
individual endoscopists in the reporting of macroscopic findings thought to be
representative of duodenitis, meaning that some other patients may have been
misclassified as having functional, rather than organic, disease. However, given that
we did not classify histologic gastritis as organic disease, and we treated gastric and
duodenal erosions as organic disease, it is unlikely that that these issues will have led
to any great degree of misclassification.
As this study was conducted within usual clinical practice, and there is no
accepted gold-standard for the diagnosis of FD, other than a normal endoscopy, we
did not mandate a minimum diagnostic work-up such as complete blood count, C-
reactive protein, celiac serology, abdominal ultrasound scan, or gastric scintigraphy in
all individuals. Our study assumed that where initial blood tests were abnormal, these
would have prompted the responsible physician to request further appropriate
investigations to exclude organic disease. However, where celiac serology was
positive, distal duodenal biopsy was performed, and those individuals with celiac
disease were classified as having organic disease within our analyses. The relevance
of these issues is debatable. A previous meta-analysis has demonstrated that the
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prevalence of celiac disease in patients with dyspeptic symptoms is no higher than
among individuals without, 23 emptying rates during gastric scintigraphy appear to
correlate poorly with symptoms, 24 and the yield of abdominal ultrasound in detecting
relevant organic pathology in dyspeptic patients with a normal upper GI endoscopy
was <5% in one primary care-based study. 25
There have been few studies that have attempted to validate the Rome III
criteria for FD, to our knowledge, to date. In a small study from Malaysia, Lee et al.
applied a Malaysian translation of the Rome III questionnaire for the functional GI
disorders in primary care. 26 The authors reported that 19 patients met criteria for FD,
of whom 16 had a negative endoscopy, giving a positive predictive value of 84%. In a
larger Pakistani study, 191 patients fulfilling Rome III criteria for FD underwent
upper GI endoscopy, and true FD was confirmed in 136, giving a positive predictive
value of 71%. 27 However, as neither of these studies reported endoscopic findings
among those without Rome III FD the positive and negative LRs cannot be calculated.
A previous meta-analysis of population-based studies that performed
endoscopy in subjects with dyspepsia reported that 23.6% had clinically significant
findings after investigation. 16 Despite being conducted in a secondary care setting,
the proportion of individuals who met the Rome III criteria for FD with organic
disease at endoscopy in our study was almost identical. The commonest organic
findings were erosive esophagitis or peptic ulcer disease, with upper GI malignancy
occurring in <0.3%. In a large primary care-based study that performed upper GI
endoscopy in over 2700 patients with Rome II FD, 23% had organic disease and only
0.2% gastro-esophageal malignancy. 28 These data are remarkably consistent,
highlighting the fact that three-quarters of individuals who meet criteria for FD have
Ford et al. 21 of 39
no organic explanation for their symptoms detected at endoscopy, and reinforcing that
upper GI cancer is extremely rare in patients with dyspepsia.
The FD symptom subtypes were developed as a result of factor analysis
studies, 29-31 as well as reports that up to 80% of patients reported symptom
aggravation after ingestion of a meal, 32 and the observation that response to therapy
differed by symptom subgroup in clinical trials of proton pump inhibitors in FD. 33
Novel therapies for dyspepsia continue to be developed and tested based on these
subtypes. 34, 35 Despite this, the proportion of patients who met criteria for EPS and
PDS who demonstrated organic findings after upper GI endoscopy in our study was
broadly comparable. When one also considers the substantial degree of overlap we,
and others, 36, 37 have observed between EPS and PDS, this suggests that the division
of FD into subtypes may be artificial and of little clinical utility.
The Rome criteria are due to be revised in 2016. In terms of their accuracy in
predicting a diagnosis of FD after upper GI endoscopy, the sensitivity analyses we
conducted suggest that further refinement based on the addition or exclusion of other
symptom items are unlikely to enhance their performance to any great extent. Our
data could therefore be interpreted as calling into question the rationale for the Rome
process as a whole, suggesting that an entirely new approach may be required. They
also support the assertions of others that the division of FD into subtypes are, at
present, potentially arbitrary in secondary care and should, perhaps, be reconsidered.
In addition, the EPS subtype appears to be too restrictive, with only a very small
proportion of individuals with FD meeting criteria for EPS, a finding that has been
reported elsewhere. 38
In the future, the incorporation of biomarkers into the diagnostic criteria for
FD may improve their accuracy in predicting true FD, and also allow clearer
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separation between the proposed subtypes. One potential candidate is the presence of
duodenal eosinophilia which has been associated with FD. 39 Some investigators have
demonstrated that symptoms in FD appear to be related to meal ingestion, 32, 40
suggesting the inclusion of questions that explore a temporal association between
symptoms and food intake may be fruitful as part of the Rome IV process. However,
this may lead to confusion with gastroparesis, in which postprandial pain is also
common. 41 Another approach could be the inclusion of other GI or non-GI symptoms
within the Rome IV criteria. A Japanese study reported that the use of concomitant
lower GI symptoms suggestive of a functional bowel disorder accurately predicted the
presence of FD, 42 while van Oudenhove et al. have shown that the incorporation of
psychosocial factors such as anxiety, depression, and somatization may enhance the
accuracy of current diagnostic criteria. 43
In summary, all of the diagnostic criteria we examined performed only
modestly in predicting a diagnosis of FD, and the prevalence of erosive esophagitis
was almost identical when a broad definition of FD, which includes heartburn, was
used compared with the Rome III criteria, which exclude heartburn from the
definition. These data highlight the fact that, despite continued attempts to better
discriminate between functional and organic causes of dyspepsia, a definitive
approach to this diagnostic dilemma remains elusive.
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Table 1. Demographics and Baseline Characteristics of Patients Undergoing
Upper GI Endoscopy and Providing Complete Rome III Symptom Data,
Compared with Those Who Did Not Undergo Upper GI Endoscopy.
Underwent upper GI
endoscopy and
provided complete
Rome III symptom data
(n = 1452)
Did not undergo
upper GI
endoscopy
(n = 2619)
P value*
Mean age (SD) 48.4 (17.1) 46.8 (18.0) 0.005
Mean body mass index
(SD)
27.3 (6.2) 26.9 (6.1) 0.03
Female gender (%) 913 (62.9) 1599 (61.1) 0.25
Tobacco user (%) 321 (22.1) 499 (19.1) 0.04
Alcohol user (%) 800 (55.1) 1536 (58.6) 0.01
Marital status (%)
Married or co-habiting
Divorced or separated
Never married
Widowed
866 (59.6)
168 (11.6)
336 (23.1)
65 (4.5)
1529 (58.4)
288 (11.0)
636 (24.3)
118 (4.5)
0.47
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Educational level (%)
Elementary
High school
College or technical
school
University
Postgraduate
67 (4.6)
433 (29.8)
437 (30.1)
328 (22.6)
160 (11.0)
101 (3.9)
724 (27.6)
756 (28.9)
692 (26.4)
259 (9.9)
0.12
Ethnicity (%)
White Caucasian
South Asian
Middle-Eastern
First Nations
African
South-East Asian
Latin-American
1249 (86.0)
20 (1.4)
27 (1.9)
22 (1.5)
23 (1.6)
21 (1.4)
17 (1.2)
2324 (88.7)
38 (1.5)
29 (1.1)
16 (0.6)
28 (1.1)
27 (1.0)
18 (0.7)
0.002
Met Rome III criteria
for FD (%)
722 (49.7) 750 (28.6) < 0.001
*P value for independent samples tWHVWIRUFRQWLQXRXVGDWDDQG3HDUVRQȤ2 for
comparison of categorical data.
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Table 2. Prevalence of Organic Disease in Patients Meeting the Rome III Criteria
for FD, Compared with Those Who Did Not.
Met Rome III
criteria for FD
(n = 722)
Did not meet Rome III
criteria for FD
(n = 730)
P
value*
Erosive esophagitis (%) 81 (11.2) 109 (14.9) 0.04
Barrett’s esophagus (%) 31 (4.3) 33 (4.5) 0.90
Benign esophageal
stricture (%)
2 (0.3) 10 (1.4) 0.04
Schatzki ring (%) 8 (1.1) 15 (2.1) 0.21
Esophageal candidiasis
(%)
6 (0.8) 7 (1.0) 1.00
Eosinophilic esophagitis
(%)
1 (0.1) 12 (1.6) 0.003
Esophageal squamous
cell carcinoma (%)
1 (0.1) 2 (0.3) 1.00
Esophageal
adenocarcinoma (%)
0 (0) 1 (0.1) 1.00
Gastric ulcer (%) 31 (4.3) 43 (5.9) 0.21
Gastric erosions (%) 9 (1.2) 6 (0.8) 0.59
Gastric carcinoma (%) 1 (0.1) 2 (0.3) 1.00
Duodenal ulcer (%) 13 (1.8) 9 (1.2) 0.50
Duodenal erosions (%) 3 (0.4) 3 (0.4) 0.99
H. pylori-positive (%) 54 (7.5) 53 (7.3) 0.92
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Celiac disease (%) 15 (2.1) 22 (3.0) 0.32
Upper GI Crohn’s
disease (%)
1 (0.1) 2 (0.3) 1.00
*P value for Fisher’s exact test for comparison of categorical data.
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Table 3. Prevalence of Organic Disease in Patients Meeting the Rome III Criteria
for FD, According to Symptom Subtype.
Met criteria for
EPS alone
(n = 24)
Met criteria for
PDS alone
(n = 663)
Met criteria for
EPS and PDS
(n = 35)
Erosive esophagitis (%) 1 (4.2) 79 (11.9) 1 (2.9)
Barrett’s esophagus (%) 2 (8.3) 28 (4.2) 1 (2.9)
Benign esophageal
stricture (%)
1 (4.2) 1 (0.2) 0 (0)
Schatzki ring (%) 0 (0) 8 (1.2) 0 (0)
Esophageal candidiasis
(%)
1 (4.2) 5 (0.8) 0 (0)
Eosinophilic esophagitis
(%)
1 (4.2) 0 (0) 0 (0)
Esophageal squamous
cell carcinoma (%)
0 (0) 1 (0.2) 0 (0)
Esophageal
adenocarcinoma (%)
0 (0) 0 (0) 0 (0)
Gastric ulcer (%) 1 (4.2) 30 (4.5) 0 (0)
Gastric erosions (%) 0 (0) 9 (1.4) 0 (0)
Gastric carcinoma (%) 0 (0) 1 (0.2) 0 (0)
Duodenal ulcer (%) 0 (0) 13(2.0) 0 (0)
Duodenal erosions (%) 0 (0) 3 (0.5) 0 (0)
H. pylori-positive (%) 2 (8.3) 51 (7.7) 1 (2.9)
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Celiac disease (%) 2 (8.3) 13 (2.0) 0 (0)
Upper GI Crohn’s
disease (%)
0 (0) 1 (0.2) 0 (0)
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Table 4. Sensitivity, Specificity, Positive and Negative Predictive Values, and Positive and Negative Likelihood Ratios for the Rome III
Criteria, Rome II Criteria, and a Broad Definition of FD.
Sensitivity
(95% CI)
Specificity
(95% CI )
Positive
predictive value
(95% CI)
Negative
predictive value
(95% CI)
Positive
likelihood ratio
(95% CI)
Negative
likelihood ratio
(95% CI)
Rome III FD 60.7%
(57.5% – 63.9%)
68.7%
(64.6% – 72.6%)
76.5%
(73.2% – 79.4 %)
51.1%
(47.4% – 54.8%)
1.94
(1.69 – 2.22)
0.57
(0.52 – 0.63)
Rome III EPS 7.1%
(5.4% – 9.2%)
98.9%
(98.0% – 99.4%)
84.8%
(73.5% – 91.8%)
56.0%
(53.4% – 58.5%)
6.63
(3.28 – 13.39)
0.94
(0.92 – 0.96)
Rome III EPS
(less restrictive
definition)
56.7%
(53.0% – 60.3%)
87.3%
(84.8% – 89.4%)
79.0%
(75.2% – 82.3%)
70.5%
(67.7% – 73.2%)
4.46
(3.69 – 5.38)
0.50
(0.45 – 0.54)
Rome III PDS 65.7%
(62.4% – 68.9%)
74.9%
(71.4% – 78.1%)
76.7%
(73.4% – 79.6%)
63.5%
(60.1% – 66.9%)
2.62
(2.27 – 3.02)
0.46
(0.41 – 0.51)
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Rome III PDS
(excluding
heartburn)
32.5%
(29.3% – 35.8%)
89.6%
(87.0% – 91.7%)
79.5%
(74.8% – 83.5%)
51.7%
(48.7% – 54.6%)
3.12
(2.44 – 4.00)
0.75
(0.71 – 0.80)
Rome II FD 71.4%
(68.4% –74.2%)
55.6%
(51.5% – 59.7%)
73.5%
(70.5% – 76.2%)
53.0%
(49.0% – 57.1%)
1.61
(1.45 – 1.78)
0.51
(0.45 – 0.58)
Broad definition
of FD
92.0%
(90.1% – 93.5%)
28.6%
(25.0% – 32.5%)
69.5%
(67.0% – 71.9%)
67.0%
(60.8% – 72.6%)
1.29
(1.22 – 1.36)
0.28
(0.22 – 0.36)
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FIGURE LEGENDS
Figure 1. Flow of Study Participants.
4224 consecutive
patients enrolled
1605 patients
underwent
complete upper GI
endoscopy
2619 patients did
not undergo upper
GI endoscopy
1452 patients
provided complete
Rome III symptom
and upper GI
endoscopy data
153 patients did
not provide
complete
symptom or upper
GI endoscopy
data
